Dose-ranging antiemetic trial of high-dose oral metoclopramide

L. B. Tyson, Richard J. Gralla, M. G. Kris, C. W. Young, R. A. Clark

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The present trial with high oral doses of metoclopramide was undertaken to (a) determine a well-tolerated dosage of oral metoclopramide; (b) measure the blood levels achieved with these oral doses; (c) determine the side effects of high doses; and (d) observe for antiemetic efficacy. Thirty-six patients receiving emesis-producing chemotherapy consisting primarily of high intravenous (i.v.) doses of cyclophosphamide plus adriamycin or cisplatin received 48 courses of oral metoclopramide. The metoclopramide dosage was escalated in six steps from 0.5 to 3.0 mg/kg and was given 1/2 h before chemotherapy, then 1 1/2 , 3 1/2 , 7 1/2 , 11 1/2 , and 15 1/2 h after chemotherapy. Diphenhydramine (50 mg orally) was given with the first, third, and fifth dosages. Toxicity was generally mild, not dose related, and similar to that observed with the i.v. drug with the exception of an increased incidence of acute dystonic reactions. Antiemetic effects were observed at each dose level. In patients receiving oral metoclopramide doses of 2 or 3 mg/kg, all achieved serum levels > 1,000 ng/ml. High-dosage oral metoclopramide was well tolerated and demonstrated antiemetic effects at the dose levels explored. We recommend 2-3 mg/kg oral metoclopramide doses with 50 mg diphenhydramine for use in future trials.

Original languageEnglish (US)
Pages (from-to)239-243
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume12
Issue number3
StatePublished - 1989
Externally publishedYes

Fingerprint

Metoclopramide
Antiemetics
Diphenhydramine
Drug Therapy
Doxorubicin
Cyclophosphamide
Cisplatin
Vomiting
Incidence
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tyson, L. B., Gralla, R. J., Kris, M. G., Young, C. W., & Clark, R. A. (1989). Dose-ranging antiemetic trial of high-dose oral metoclopramide. American Journal of Clinical Oncology: Cancer Clinical Trials, 12(3), 239-243.

Dose-ranging antiemetic trial of high-dose oral metoclopramide. / Tyson, L. B.; Gralla, Richard J.; Kris, M. G.; Young, C. W.; Clark, R. A.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 12, No. 3, 1989, p. 239-243.

Research output: Contribution to journalArticle

Tyson, LB, Gralla, RJ, Kris, MG, Young, CW & Clark, RA 1989, 'Dose-ranging antiemetic trial of high-dose oral metoclopramide', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 12, no. 3, pp. 239-243.
Tyson, L. B. ; Gralla, Richard J. ; Kris, M. G. ; Young, C. W. ; Clark, R. A. / Dose-ranging antiemetic trial of high-dose oral metoclopramide. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1989 ; Vol. 12, No. 3. pp. 239-243.
@article{71323a3fa89b45c19426a09b3a0887db,
title = "Dose-ranging antiemetic trial of high-dose oral metoclopramide",
abstract = "The present trial with high oral doses of metoclopramide was undertaken to (a) determine a well-tolerated dosage of oral metoclopramide; (b) measure the blood levels achieved with these oral doses; (c) determine the side effects of high doses; and (d) observe for antiemetic efficacy. Thirty-six patients receiving emesis-producing chemotherapy consisting primarily of high intravenous (i.v.) doses of cyclophosphamide plus adriamycin or cisplatin received 48 courses of oral metoclopramide. The metoclopramide dosage was escalated in six steps from 0.5 to 3.0 mg/kg and was given 1/2 h before chemotherapy, then 1 1/2 , 3 1/2 , 7 1/2 , 11 1/2 , and 15 1/2 h after chemotherapy. Diphenhydramine (50 mg orally) was given with the first, third, and fifth dosages. Toxicity was generally mild, not dose related, and similar to that observed with the i.v. drug with the exception of an increased incidence of acute dystonic reactions. Antiemetic effects were observed at each dose level. In patients receiving oral metoclopramide doses of 2 or 3 mg/kg, all achieved serum levels > 1,000 ng/ml. High-dosage oral metoclopramide was well tolerated and demonstrated antiemetic effects at the dose levels explored. We recommend 2-3 mg/kg oral metoclopramide doses with 50 mg diphenhydramine for use in future trials.",
author = "Tyson, {L. B.} and Gralla, {Richard J.} and Kris, {M. G.} and Young, {C. W.} and Clark, {R. A.}",
year = "1989",
language = "English (US)",
volume = "12",
pages = "239--243",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Dose-ranging antiemetic trial of high-dose oral metoclopramide

AU - Tyson, L. B.

AU - Gralla, Richard J.

AU - Kris, M. G.

AU - Young, C. W.

AU - Clark, R. A.

PY - 1989

Y1 - 1989

N2 - The present trial with high oral doses of metoclopramide was undertaken to (a) determine a well-tolerated dosage of oral metoclopramide; (b) measure the blood levels achieved with these oral doses; (c) determine the side effects of high doses; and (d) observe for antiemetic efficacy. Thirty-six patients receiving emesis-producing chemotherapy consisting primarily of high intravenous (i.v.) doses of cyclophosphamide plus adriamycin or cisplatin received 48 courses of oral metoclopramide. The metoclopramide dosage was escalated in six steps from 0.5 to 3.0 mg/kg and was given 1/2 h before chemotherapy, then 1 1/2 , 3 1/2 , 7 1/2 , 11 1/2 , and 15 1/2 h after chemotherapy. Diphenhydramine (50 mg orally) was given with the first, third, and fifth dosages. Toxicity was generally mild, not dose related, and similar to that observed with the i.v. drug with the exception of an increased incidence of acute dystonic reactions. Antiemetic effects were observed at each dose level. In patients receiving oral metoclopramide doses of 2 or 3 mg/kg, all achieved serum levels > 1,000 ng/ml. High-dosage oral metoclopramide was well tolerated and demonstrated antiemetic effects at the dose levels explored. We recommend 2-3 mg/kg oral metoclopramide doses with 50 mg diphenhydramine for use in future trials.

AB - The present trial with high oral doses of metoclopramide was undertaken to (a) determine a well-tolerated dosage of oral metoclopramide; (b) measure the blood levels achieved with these oral doses; (c) determine the side effects of high doses; and (d) observe for antiemetic efficacy. Thirty-six patients receiving emesis-producing chemotherapy consisting primarily of high intravenous (i.v.) doses of cyclophosphamide plus adriamycin or cisplatin received 48 courses of oral metoclopramide. The metoclopramide dosage was escalated in six steps from 0.5 to 3.0 mg/kg and was given 1/2 h before chemotherapy, then 1 1/2 , 3 1/2 , 7 1/2 , 11 1/2 , and 15 1/2 h after chemotherapy. Diphenhydramine (50 mg orally) was given with the first, third, and fifth dosages. Toxicity was generally mild, not dose related, and similar to that observed with the i.v. drug with the exception of an increased incidence of acute dystonic reactions. Antiemetic effects were observed at each dose level. In patients receiving oral metoclopramide doses of 2 or 3 mg/kg, all achieved serum levels > 1,000 ng/ml. High-dosage oral metoclopramide was well tolerated and demonstrated antiemetic effects at the dose levels explored. We recommend 2-3 mg/kg oral metoclopramide doses with 50 mg diphenhydramine for use in future trials.

UR - http://www.scopus.com/inward/record.url?scp=0024311758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024311758&partnerID=8YFLogxK

M3 - Article

C2 - 2658539

AN - SCOPUS:0024311758

VL - 12

SP - 239

EP - 243

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -